Shares of badly battered Ariad Pharmaceuticals took a fresh dive this morning after the biotech reported that it is jerking its leukemia drug Iclusig from the market, two weeks after the drug developer opted to shutter its Phase III confirmatory study after seeing evidence of an elevated risk of blood clots among patients.
Once expected to crest at $2.52 billion a year, most analysts now don't see AstraZeneca's blood-thinner Brilinta hitting the $1 billion blockbuster mark, with a poor impact in the U.S. market dragging down projections.
When the FDA puts drugs on the fast track for approval, they do make it to market sooner. But they're tested for a shorter period of time than are drugs reviewed under the agency's standard process, according to a new study in the Journal of the American Medical Association. And that has researchers worried.
The FDA's move to put tighter controls on combo pain drugs like Vicodin that contain hydrocodone with over-the-counter painkillers like aspirin have it again balancing its role as a regulator concerned about the safety and effectiveness of drugs with growing concerns about overdose deaths and addition.
A new study finds that the drug lingers in the bodies of patients long after they've stopped using it, sometimes even for years.
Merck's experimental anacetrapib is one of those massively expensive lottery programs that can spur dreams of huge revenue streams.
To safely deliver the very powerful anti-cancer compound staurosporine (STS), researchers at the University of California, San Diego School of Medicine have developed a liposome-based method to stabilize the drug and encapsulate it on its way to cancerous cells. STS, originally isolated from a bacterium in 1977, according to a UCSD report, causes apoptosis, or cell death, and for more than 35 years has been too strong for use as a cancer drug.
Ariad Pharmaceuticals' October fall from grace has wiped almost $3 billion from the company's market cap, and now the beleaguered drugmaker is putting on hold its plans to move into a built-to-suit new headquarters in Cambridge, MA's biotech hub.
As the government searches for ways to limit Medicare spending, it may eye a new report that says in some regions, older patients don't get the drugs they need--and others are getting drugs that can be dangerous to their health. Prescription drug use among Medicare patients and spending by region is wildly inconsistent, it says, and in some cases, the health status of patients in the region has little to do with it.
The Institute for Safe Medication Practices has flagged its latest set of side-effect reports to the FDA--and once again, anticoagulant drugs are at the top. Boehringer Ingelheim's Pradaxa, a new-generation pill, and the old standard therapy warfarin together accounted for more than 1,100 of the adverse events reported direcctly to the FDA.